Annalyn Welp

Correction to: Nature https://doi.org/10.1038/s41586-025-09203-8 Published online 2 July 2025 In the version of this article initially published, a patient’s KRAS mutation was mistakenly documented as a PIK3CA mutation in the original data.

Abstract Immune checkpoint blockade (ICB) therapy is effective against many cancers, although resistance remains a major issue and new strategies are needed to improve clinical outcomes1,2,3,4,5. Here we studied ICB response in a cohort of patients with ovarian clear cell carcinoma—a cancer type that poses considerable clinical challenges and lacks effective therapies6,7,8.

2. Discussion 2.1. Guidelines for Screening Several different sets of cervical cancer screening guidelines are currently published and are compared in Table 1. On an international level, the WHO published an updated screening guideline in 2021 recommending cervical cancer screening in all women in the general population starting at age 30 with HPV DNA testing only rather than with cytology or VIA.